Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roll-over study of sabatolimab for patients benefiting from prior Novartis-sponsored sabatolimab trials
2021-004422-30Phase 2Active
- Sponsor
- Novartis
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sabatolimab in myelodysplastic syndrome (MDS), sponsored by Novartis. Primary endpoint: Safety (AEs and SAEs). Started May 2022; status: active.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2021-004422-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004422-30.